MRK vs MSFT: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
Microsoft Corporation · Technology
$372.20
+32.4% upside to fair value
High Conviction
Grade A
QuantHub Verdict
MSFT has more upside to fair value
(+32.4%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MSFT |
| Current Price |
$121.42 |
$372.20 |
| Fair Value Estimate |
$118.00 |
$493.00 |
| Upside to Fair Value |
-2.9%
|
+32.4%
|
| Market Cap |
$300.2B |
$2,763.6B |
| Forward P/E |
14.0x
|
22.0x
|
| EV / EBITDA |
11.8x
|
17.5x
|
| Price / Sales |
4.1x
|
9.1x
|
| Price / FCF |
21.4x
|
35.8x
|
| Revenue Growth YoY |
+1.3%
|
+14.9%
|
| Gross Margin |
81.5%
|
68.8%
|
| Operating Margin |
41.2%
|
45.6%
|
| Return on Equity |
34.7%
|
29.6%
|
| Dividend Yield |
3.1% |
0.94% |
| FCF Yield |
4.7%
|
2.8%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Microsoft is the world's largest software company, operating a three-pillar empire across cloud (Azure), productivity (Office 365/Teams), and personal computing (Windows/Xbox). Azure is the second-largest cloud platform globally with 24% market share and growing at 38-39% in constant currency, while Microsoft Cloud revenue crossed $168.9B in FY2025. The stock has dropped 33% from its highs to $37…
Accumulation Zones
| Metric |
MRK |
MSFT |
| Zone Low |
$88.00 |
$370.00 |
| Zone High |
$100.00 |
$419.00 |
| In Buy Zone? |
No
|
Yes
|